首页> 美国卫生研究院文献>Molecular Therapy. Methods Clinical Development >Delta-1 Functionalized Hydrogel Promotes hESC-Cardiomyocyte Graft Proliferation and Maintains Heart Function Post-Injury
【2h】

Delta-1 Functionalized Hydrogel Promotes hESC-Cardiomyocyte Graft Proliferation and Maintains Heart Function Post-Injury

机译:Delta-1功能化水凝胶可促进hESC-心肌移植的增殖并在受伤后维持心脏功能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Current cell transplantation techniques are hindered by small graft size, requiring high cell doses to achieve therapeutic cardiac remuscularization. Enhancing the proliferation of transplanted human embryonic stem cell-derived cardiomyocytes (hESC-CMs) could address this, allowing an otherwise subtherapeutic cell dose to prevent disease progression after myocardial infarction. In this study, we designed a hydrogel that activates Notch signaling through 3D presentation of the Notch ligand Delta-1 to use as an injectate for transplanting hESC-CMs into the infarcted rat myocardium. After 4 weeks, hESC-CM proliferation increased 2-fold and resulted in a 3-fold increase in graft size with the Delta-1 hydrogel compared to controls. To stringently test the effect of Notch-mediated graft expansion on long-term heart function, a normally subtherapeutic dose of hESC-CMs was implanted into the infarcted myocardium and cardiac function was evaluated by echocardiography. Transplantation of the Delta-1 hydrogel + hESC-CMs augmented heart function and was significantly higher at 3 months compared to controls. Graft size and hESC-CM proliferation were also increased at 3 months post-implantation. Collectively, these results demonstrate the therapeutic approach of a Delta-1 functionalized hydrogel to reduce the cell dose required to achieve functional benefit after myocardial infarction by enhancing hESC-CM graft size and proliferation.
机译:当前的细胞移植技术由于移植物尺寸小而受到阻碍,需要高剂量的细胞才能实现治疗性的心肌再生。增强移植的人类胚胎干细胞衍生的心肌细胞(hESC-CMs)的增殖可以解决此问题,从而允许采用其他亚治疗细胞剂量来预防心肌梗塞后疾病的进展。在这项研究中,我们设计了一种水凝胶,可通过Notch配体Delta-1的3D呈现激活Notch信号传导,用作将hESC-CM移植到梗死大鼠心肌中的注射剂。 4周后,与对照组相比,Delta-1水凝胶的hESC-CM增殖增加了2倍,导致移植物大小增加了3倍。为了严格测试Notch介导的移植物扩张对长期心脏功能的影响,将正常亚治疗剂量的hESC-CMs植入梗塞的心肌,并通过超声心动图评估心脏功能。与对照组相比,Delta-1水凝胶+ hESC-CM的移植增强了心脏功能,并在3个月时显着更高。移植后3个月,移植物的大小和hESC-CM的增殖也增加了。总的来说,这些结果证明了通过增强hESC-CM移植物的大小和增殖来减少Delta-1功能化水凝胶的治疗方法,以减少获得心肌梗塞后功能功能所需的细胞剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号